drug development

Michael Gottesman Reflects on Tenure Leading Intramural Research Program

Renowned Cancer Scientist Stepped Down After 29 Years in Position

Dr. Michael Gottesman

Dr. Michael Gottesman has been a member of the NIH community since 1976. He has held many positions throughout his tenure, including spending 29 years as the Deputy Director of Intramural Research (DDIR). He stepped down as DDIR this past year and has returned to focusing solely on being Chief of the Lab of Cell Biology at the National Cancer Institute (NCI). Dr. Gottesman recently participated in an interview with the NIH Office of Technology Transfer, excerpts of which we are re-posting here on the "I Am Intramural" blog. 

A New Approach to Male Birth Control

Research in Cells Shows Promise for an Alternative Way to Halt Sperm Production

birth control pills

Birth control has long been mostly one-sided, as the vast majority of contraceptive methods are intended exclusively for women. However, recent IRP research has shown the potential of a new approach towards creating a reversible method of male contraception.

Women have a vast array of contraceptive options available to them, from ‘the pill’ to intrauterine devices (IUDs) and other products. However, for men, the only options aside from condoms are safe but irreversible surgical procedures. More than 40 percent of pregnancies in the U.S. are unintended, and additional options for male birth control could help reduce that number.

Old Drugs Find New Potential Against Hepatitis C

IRP Research Highlights a Novel Target to Stop Viral Infections

drug-screening robot

On July 28, health providers, researchers, patients, advocates, and governments across the globe observe World Hepatitis Day. Like this year’s theme, ‘Hepatitis Can’t Wait,’ IRP researchers are wasting no time utilizing the unique resources at the National Institutes of Health to identify innovative ways to combat the virus.

IRP Distinguished Investigator T. Jake Liang, M.D., for example, has focused his life’s work on understanding how hepatitis viruses infect, replicate, and persist in cells. The viruses he studies, hepatitis B and C, together affect more than 10 percent of the worlds’ population and are the most common causes of chronic liver disease and liver cancer. The two viruses were originally discovered in the 1980s by another IRP scientist, Harvey J. Alter, M.D., who shared the Nobel Prize in Medicine for that work in 2020. Nearly three decades later, Dr. Liang’s lab at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) worked with scientists at the National Center for Advancing Translational Sciences (NCATS) to develop a novel test to screen thousands of molecules using a technology called high-throughput screening, which led to the discovery of several compounds with the potential to block hepatitis C infection.

Experimental Compound Supercharges Cellular Power Plants

Treatment Approach Could Combat Obesity and Its Consequences

light bulb

When your phone or laptop is low on power, you simply connect it to a charger and find the nearest electrical outlet, but the process of restoring lagging energy production in our cells is not nearly as simple. However, a new IRP study has identified a promising approach for doing just that, which could lead to new treatments for obesity and related metabolic ailments like heart disease and diabetes.

A Ray of Hope for a Rare and Deadly Skin Cancer

IRP Research Leads to First FDA-Approved Therapy for Merkel Cell Carcinoma

Dr. James Gulley talking with a patient

May is Skin Cancer Awareness Month. Skin cancers are the most common cancer in the U.S., affecting as many as five million people every year. Yet the rarest of these cancers is also one of the deadliest. Merkel cell carcinoma affects about 3,000 Americans each year, and until recently a lack of effective treatments meant only half of patients survived five years or longer after diagnosis. The median survival was nine months.

This bleak outlook changed radically in 2017 with the US Food and Drug Administration (FDA) approval of a new immunotherapy drug called avelumab. Developed through a collaboration between IRP researchers and the pharmaceutical company EMD Serono, Inc., and marketed as Bavencio, avelumab was the first treatment approved specifically for Merkel cell carcinoma.

IRP Supercomputer Enables Rapid Response to Coronavirus

Biowulf Lends Massive Computing Power to NIH Research Efforts

rows of computer servers

Nations around the world are bringing every weapon in their arsenals to the fight against the COVID-19 pandemic: vaccines, new and existing therapeutics, personal protective equipment like face masks, and enough hand sanitizer to fill the Atlantic Ocean. The NIH community is contributing to this unprecedented effort with a tool that no other research institution can claim: Biowulf, the world’s most powerful supercomputer solely dedicated to biomedical research.

Pandemic Brings All Hands on Deck

IRP Investigators Begin Hundreds of New Coronavirus-Related Studies

coronavirus particles (gold) emerging from an infected cell

Within just a few months after COVID-19 began spreading in the United States, IRP researchers had already made numerous important contributions to the fight against the deadly virus. Scientific knowledge about the disease continues to expand at a unprecedented pace, and the IRP will continue to play a major role in this effort over the coming months and years. In fact, nearly 300 new intramural research projects related to the novel coronavirus are currently starting up or have already begun.

Modified Hormone Protects Damaged Hearts

Alteration Helps Prospective Drug Persist Longer in Rodents’ Bodies

transparent view of the body with heart highlighted

Even the best construction crew cannot repair a building if it is called away from the site before it can begin its work. Similarly, while the body’s ability to cleanse itself of chemicals can prevent the buildup of toxins, it can also stymie the therapeutic effects of medications. IRP researchers recently found that modifying a prospective treatment for heart failure to help it persist longer in the body boosted its beneficial effects in mice.

IRP’s Michael Gottesman Elected to National Academy of Sciences

NIH Investigator Recognized for Insights into Drug Resistance in Cancer

Dr. Michael Gottesman

The National Academy of Sciences, a private society established in 1863, is made up of the United States’ most distinguished scientific scholars, including nearly 500 members who have won Nobel Prizes. Members of the NAS are elected by their peers and charged with the responsibility of providing independent, objective advice on national matters related to science and technology in an effort to further scientific innovation in the U.S.

IRP Senior Investigator Michael Gottesman, M.D., is one of four IRP researchers who were elected to the Academy over the past two years. At the NIH, Dr. Gottesman plays two very different but equally important roles, serving as Deputy Director for Intramural Research while also leading the Laboratory of Cell Biology at the National Cancer Institute (NCI).

Postbac Life: A Week in an IRP Lab

postbac IRTA Lindsey Jay examining a slide using a microscope

What does a postbac actually do in the NIH IRP? Maybe you have an image of someone mixing colorful chemicals together like a mad scientist (which sometimes isn’t too far from the truth).

Although I am not creating any diabolical concoctions, I am kept quite busy running tests to examine whether our treatments reverse the effects of lung fibrosis, a thickening and scarring of lung tissue. Here’s what a typical week looks like for me.